Publication: New Horizons: Emerging Antidiabetic Medications
New Horizons: Emerging Antidiabetic Medications
Date
Date
Date
Citations
Mingrone, G., Castagneto-Gissey, L., & Bornstein, S. R. (2022). New Horizons: Emerging Antidiabetic Medications. Journal of Clinical Endocrinology & Metabolism, 107(12), e4333–e4340. https://doi.org/10.1210/clinem/dgac499
Abstract
Abstract
Abstract
Over the past century, since the discovery of insulin, the therapeutic offer for diabetes has grown exponentially, in particular for type 2 diabetes (T2D). However, the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss. An ideal medication for T2D should target not only hyperglycemia but also insulin resistance and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the new class of GLP1 and gastric inhibitory polypeptide dual
Metrics
Views
Additional indexing
Creators (Authors)
- Mingrone, Geltrude
- Castagneto-Gissey, Lidia
- Bornstein, Stefan R
Journal/Series Title
Journal/Series Title
Journal/Series Title
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Views
Citations
Mingrone, G., Castagneto-Gissey, L., & Bornstein, S. R. (2022). New Horizons: Emerging Antidiabetic Medications. Journal of Clinical Endocrinology & Metabolism, 107(12), e4333–e4340. https://doi.org/10.1210/clinem/dgac499